文献速递胰腺与胆道疾病食管胃疾病与幽门螺杆菌

质子泵抑制剂使用与胆管炎风险:全国性队列研究

Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2019-08-25

该研究基于韩国全国代表性样本的10年随访队列,将PPI使用作为时变变量,发现PPI使用与胆管炎发生风险升高相关,年龄、性别、地区及收入调整后HR为6.06(95%CI 4.64-7.91),完全调整模型HR为5.75(95%CI 4.39-7.54),且风险在PPI治疗期间最高,停药后逐渐下降(Ptrend<.001)。

要点

  • PPI使用与胆管炎发生风险升高相关,完全调整后HR为5.75(95%CI 4.39-7.54)。
  • 风险在PPI治疗期间最高,停药后逐渐下降(Ptrend<.001)。
  • 处方PPI的医生应考虑胆管炎作为PPI使用的潜在并发症。

核心结论

  • 在这项大型队列中,PPI使用与胆管炎风险升高相关。
  • 处方PPI的医生应将胆管炎视为PPI使用的潜在并发症。

研究设计与样本

  • 全国性代表性样本的队列研究,随访10年(2003年1月1日至2013年12月31日)。
  • PPI使用从治疗索赔中识别并作为时变变量, incident胆管炎从住院和门诊就诊索赔中识别。
  • 随访共4 212 003人年,58,863名参与者至少有一次PPI处方,1 834名参与者发生胆管炎。

主要发现

  • 比较PPI使用与非使用, incident胆管炎的年龄、性别、居住地区及收入调整后HR为6.06(95%CI 4.64-7.91)。
  • 完全调整模型中关联基本不变,HR为5.75(95%CI 4.39-7.54)。
  • 风险在PPI治疗期间最高,停药后逐渐下降(Ptrend<.001)。

临床怎么用

  • 处方PPI的医生应考虑胆管炎作为PPI使用的潜在并发症。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton pump inhibitor (PPI) use may alter the gut microbiome and increase the risk of cholangitis. However, the association of PPI use with the risk of incident cholangitis has not been evaluated. AIM: To evaluate whether PPI use was associated with a higher risk of cholangitis. METHODS: This cohort study included a nationwide representative sample of the Korean general population followed up for 10 years (1 January 2003 to 31 December 2013). PPI use was identified from treatment claims and considered as a time-varying variable. Incident cholangitis was identified from hospitalisation and out-patient visit claims. RESULTS: During 4 212 003 person-years of follow-up, 58,863 participants had at least one PPI prescription and 1 834 participants developed cholangitis. The age-, sex-, residential area- and income-adjusted hazard ratio (HR) for incident cholangitis comparing PPI use with non-use was 6.06 (95% CI, 4.64-7.91). The association was essentially unchanged in fully adjusted models (HR 5.75; 95% CI, 4.39-7.54). The risk was highest during PPI treatment and decreased gradually after PPI discontinuation (Ptrend <.001). CONCLUSIONS: In this large cohort, PPI use was associated with an increased risk of cholangitis. Physicians prescribing PPIs should consider cholangitis as a potential complication of PPI use.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Min YW, Kang D, Shin JY, et al. Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study. Aliment Pharmacol Ther. 2019. PMID: 31448440. doi:10.1111/apt.15466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。